FDA Approves Two Immunotherapies for Advanced Melanoma

Metastatic melanoma patients have received very good news with the FDA’s approval of two important new immune-boosting therapies.

Read More

FDA Approves Second Targeted Combination Therapy for Advanced Melanoma

The US Food and Drug Administration (FDA) approved the combination targeted therapy vemurafenib-cobimetinib (Zelboraf-Cotellic) for about half of all patients with Stage IV melanoma that is inoperable or has metastasized throughout the body.

Read More

Members of the Media

Check out our online press kit, recent press releases, and more in the Media & Press section.

Visit the Media & Press Section

In the Spotlight